Results 61 to 70 of about 15,566 (231)

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. [PDF]

, 2020
Determining factors that contribute to interindividual and intra-individual variability in pharmacokinetics (PKs) and drug metabolism is essential for the optimal use of drugs in humans.
Alhaja, Maher, Dorrestein, Pieter C, Jarmusch, Alan K, Knight, Rob, Liyanage, Marlon, Ma, Joseph D, Momper, Jeremiah D, Tsunoda, Shirley M, Vrbanac, Alison   +8 more
core   +1 more source

From Data to Decisions: How Machine Learning and Generative Artificial Intelligence Are Redefining Precision Medicine in Kidney Transplantation

Organ Medicine, EarlyView.
This review evaluates how machine learning, multimodal integration, and generative AI optimize kidney transplant outcomes. These tools enable superior prediction and personalized therapy but face hurdles in data volume, generalizability, and ethics. Future clinical adoption depends on continued innovation and multidisciplinary collaboration to overcome
Maoxin Liao, Cheng Yang
wiley   +1 more source

CYP3A5 unexpectedly regulates glucose metabolism through the AKT–TXNIP–GLUT1 axis in pancreatic cancer

Genes and Diseases
CYP3A5 is a cytochrome P450 (CYP) enzyme that metabolizes drugs and contributes to drug resistance in cancer. However, it remains unclear whether CYP3A5 directly influences cancer progression.
Ming Shao, Qingfei Pan, Haiyan Tan, Jing Wu, Ha Won Lee, Andrew D. Huber, William C. Wright, Ji-Hoon Cho, Jiyang Yu, Junmin Peng, Taosheng Chen   +10 more
doaj   +1 more source

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects [PDF]

, 2018
Objective: We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, could be demonstrated between subjects with different CYP3A4 and CYP3A5 genotypes.
Aubert, Anne-Catherine, Baumann, Pierre, Bleiber, Gabriela, Buclin, Thierry, Eap, Chin, Golay, Kerry, Hustert, Elisabeth, Kerb, Reinhold, Telenti, Amalio   +8 more
core  

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor [PDF]

, 2011
Purpose: Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.
Paul Hamberg, Margaret M. Woo, Lin-Chi Chen, Jaap Verweij, Maria Grazia Porro, Lily Zhao, Wenkui Li, Diane van der Biessen, Sunil Sharma, Thomas Hengelage, Maja de Jonge   +10 more
core   +2 more sources

Harnessing Phytochemicals for Brain Cancer Therapy: Insights Into Medulloblastoma and Glioblastoma Treatment

Phytochemical Analysis, EarlyView.
ABSTRACT Primary brain tumors are life‐threatening diseases. Glioblastoma is the most aggressive type with a poor prognosis. Medulloblastoma is the most common pediatric brain tumor. While surgical treatments often result in recurrences owing to the complex nature of the tumor microenvironment, conventional treatments lower the quality of life of ...
Ilkay Irem Ozbek, Mesra Aktas, Hale Saybasili, Kutlu O. Ulgen   +3 more
wiley   +1 more source

Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures [PDF]

Drug Metabolism and Disposition, 2015
A recent publication by [Lu et al. (2014)][1] described the effects of the CYP3A5 genotype on Selzentry/Celsentri (maraviroc) concentrations. Maraviroc is a chemokine (C-C motif) receptor 5 inhibitor approved for the treatment of human immunodeficiency virus (HIV) infection ([Dorr et al., 2005 ...
Manoli, Vourvahis, Lynn, McFadyen, Jayvant, Heera, Andrew, Clark   +3 more
openaire   +2 more sources

Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer

Annals of Human Biology, 2023
Background CYP3A4 and CYP3A5 are biologically potential genes responsible for prostate cancer. Aim We aimed to analyse the expression and association of CYP3A4 and CYP3A5 genes in prostate cancer.
Sm Faysal Bellah, Md. Abdus Salam, S. M. Saker Billah, Md Rezaul Karim   +3 more
doaj   +1 more source

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? [PDF]

, 2011
Purpose Neuroblastoma is the most common extracranial solid tumour in childhood. It accounts for 15% of all paediatric oncology deaths. In the last few decades, improvement in treatment outcome for high-risk patients has not occurred, with an overall ...
Francesco Bellanti, Bertil Kågedal, Oscar Della Pasqua   +2 more
core   +2 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source